- Home
- SUPN vs NAVI Comparison
SUPN vs NAVI Comparison
Compare SUPN & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- NAVI
- Stock Information
- Founded
- SUPN 2005
- NAVI 1973
- Country
- SUPN United States
- NAVI United States
- Employees
- SUPN N/A
- NAVI N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- NAVI Investment Bankers/Brokers/Service
- Sector
- SUPN Health Care
- NAVI Finance
- Exchange
- SUPN Nasdaq
- NAVI Nasdaq
- Market Cap
- SUPN 1.8B
- NAVI 1.4B
- IPO Year
- SUPN 2012
- NAVI N/A
- Fundamental
- Price
- SUPN $32.46
- NAVI $15.20
- Analyst Decision
- SUPN Hold
- NAVI Hold
- Analyst Count
- SUPN 2
- NAVI 7
- Target Price
- SUPN $36.00
- NAVI $14.00
- AVG Volume (30 Days)
- SUPN 747.3K
- NAVI 859.3K
- Earning Date
- SUPN 08-05-2025
- NAVI 07-23-2025
- Dividend Yield
- SUPN N/A
- NAVI 4.18%
- EPS Growth
- SUPN N/A
- NAVI N/A
- EPS
- SUPN 1.11
- NAVI 0.52
- Revenue
- SUPN $667,997,000.00
- NAVI $699,000,000.00
- Revenue This Year
- SUPN N/A
- NAVI N/A
- Revenue Next Year
- SUPN $12.02
- NAVI $2.85
- P/E Ratio
- SUPN $29.24
- NAVI $29.56
- Revenue Growth
- SUPN 11.82
- NAVI N/A
- 52 Week Low
- SUPN $25.94
- NAVI $10.53
- 52 Week High
- SUPN $40.28
- NAVI $16.97
- Technical
- Relative Strength Index (RSI)
- SUPN 53.20
- NAVI 71.66
- Support Level
- SUPN $31.35
- NAVI $14.60
- Resistance Level
- SUPN $32.55
- NAVI $16.07
- Average True Range (ATR)
- SUPN 0.91
- NAVI 0.44
- MACD
- SUPN 0.04
- NAVI 0.15
- Stochastic Oscillator
- SUPN 60.93
- NAVI 79.18
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in three segments: Federal Education Loans, Consumer Lending, and Business Processing. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.